



Patient Power

Peripheral T-Cell Lymphoma Updates From ASH 2018

Neel K. Gupta, MD

Division of Oncology, Lymphoma Stanford Cancer Institute
Stanford University School of Medicine

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you'll get care that's most appropriate for you.

Lee Swanson:

Hello. This is Patient Power, and I'm Lee Swanson. We're here at the American Society of Hematology conference in San Diego, and joining us is Dr. Neel Gupta from Stanford. Doctor, peripheral T-cell lymphoma, what is coming out at this conference that's exciting you about that?

Dr. Gupta:

It's a great question, and I've been most excited about the results of the ECHELON-2 study which, as you may or may not know, is a combination of standard chemotherapy with a very good and effective antibody treatment called brentuximab. And this is a really exciting study for us because it showed that the combination of the chemo drug and the antibody was very effective in treating patients with peripheral T-cell lymphoma. Overall response rates were close to 80 percent, and about 65 percent of those patients on the study had a complete response, which is really exciting news.

Lee Swanson:

So is that something that a patient can ask about now as it's coming forward, or is it...

Dr. Gupta:

That's a great question. In fact, the FDA has already looked at the data and said this looks like a real winner, and it has been FDA approved in combination with standard chemotherapy. So, yes, your doctor will already be thinking about this treatment if you have a diagnosis of peripheral T-cell lymphoma.

Lee Swanson:

And to have that conversation with your doctor, is this something that—I mean, there's peripheral T-cell lymphoma and there's peripheral T-cell lymphoma.

Dr. Gupta:

Right.

Lee Swanson:

Is this something everybody might look at? Or what patient—what's the conversation there?

Dr. Gupta:

Yes. It's a great question. I think mainly it's patients who have truly peripheral T-cell lymphoma and not so much cutaneous or skin-based lymphoma, but if you look at the results of the trial anyone with peripheral T-cell lymphoma benefited, and I think as long as you meet certain criteria for blood tests you should be eligible to receive this treatment.

Lee Swanson:

That's really encouraging news. Well, thank you very much for taking the time to be here with us.

Dr. Gupta:

Of course. My pleasure.

Lee Swanson:

We really appreciate it. I'm Lee Swanson at the American Society of Hematology conference.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you'll get care that's most appropriate for you.